Profil
Omid Karkouti is the founder of two companies.
He founded Reformer Therapeutics, Inc. and Rarebase, PBC.
At Reformer Therapeutics, Inc., he holds no specific title.
At Rarebase, PBC, he held the title of Chief Operating Officer, but was no longer active in that role.
Postes actifs de Omid Karkouti
| Sociétés | Poste | Début |
|---|---|---|
Rarebase, PBC
 Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Fondateur | - |
Anciens postes connus de Omid Karkouti
| Sociétés | Poste | Fin |
|---|---|---|
Reformer Therapeutics, Inc.
 Reformer Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Reformer Therapeutics, Inc. develops therapy for cancer treatment. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Reformer Therapeutics, Inc.
Reformer Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Reformer Therapeutics, Inc. develops therapy for cancer treatment. | Health Services |
Rarebase, PBC
Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Technology Services |
